This author has not written his bio yet.
But we are proud to say that Maria Fontanazza contributed 86 entries already.
“We like to tease that market access is an overnight sensation 20 years in the making. But in all seriousness, market access has always been ultra-important to those of us working in the space, so it’s rewarding to see greater recognition across the industry.” Andrew Gottfried, CEO of Entrée Health, discusses one of the most important and hottest topics in pharma today: market access.
It’s been a banner couple of years for Spectrum Science and CrowdPharm, and the time was simply right for the agencies to take the next transformative step.
Market access has been and continues to be an important process, and as of late many agencies have been boosting their capabilities in this area. We recently caught up with Ellen Cappellino, the new executive director of value, access, and reimbursement at Klick Health and the agency’s chief medical officer, Holly Henry, to discuss current market access issues and its future.
Mallinckrodt, which makes branded and generic drugs, first filed for bankruptcy in 2020 to address its high debt load, litigation over its allegedly deceptive marketing of highly addictive generic opioids and drug pricing disputes.
The campaign, “You Can Focus on the Things You’re Loving,” empowers patients by arming them with the information they need to understand the treatment options for chronic lymphocytic leukemia so they can focus on the activities that they enjoy.
The company’s new campaign, “Countdown at a Crossroads” featuring TV host Sherri Shepherd, shines a spotlight on how CGM technology can help people living with diabetes improve health outcomes and have a better quality of life.
Pharma companies are striving to convey the true impact of diseases on patients while continuing to empower them.
With the settlement of a big acquisition behind them and a strong portfolio of therapeutics that continues to expand, hopes for smooth sailing are on the horizon.
Last year GSK made a strategic move to focus solely on biopharma, and it is already realizing the benefits of a more targeted business.
J&J is heading into the remainder of 2023 with a new look and a revised outlook.
